Tuesday, June 02, 2009 7:50:09 PM
Re: nimo and CTIC PR
"Fool me once, shame on you; fool me twice, shame on me???"
You wouldn't be referring to the (no so) STELLAR trial data, would you
On nimo results, I would point out:
. It's a single trial that was not run per design, and recruited across changes in SOC.
. Very little Rituxin related data
. No CPOP (replacing doxorubicn in CHOP) data. The trial in question was as a single agent vs single agent (which is why the enrollment never completed).
Given all this, they seam to need another trial before cash comes rolling in.
But of course all this pales in comparison to the cardio toxicity of CTIC's debt and management.
P.S. Oddly enough, once more it seams like Adam F is likely correct for the wrong reasons.
"Fool me once, shame on you; fool me twice, shame on me???"
You wouldn't be referring to the (no so) STELLAR trial data, would you
On nimo results, I would point out:
. It's a single trial that was not run per design, and recruited across changes in SOC.
. Very little Rituxin related data
. No CPOP (replacing doxorubicn in CHOP) data. The trial in question was as a single agent vs single agent (which is why the enrollment never completed).
Given all this, they seam to need another trial before cash comes rolling in.
But of course all this pales in comparison to the cardio toxicity of CTIC's debt and management.
P.S. Oddly enough, once more it seams like Adam F is likely correct for the wrong reasons.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
